Diabetes: Freedom Meditech lands $7M to support non-invasive eye-based exams

Tue, 08/06/2013 - 1:15pm
Mass Device

Freedom Meditech plans to use its newly raised $7 million in Series B funding to forward its eye-based diabetes management suite, including an FDA-cleared diagnostic and a glucose monitor still under development.

Freedom Meditech's $7M funding round turns heads in ophthalmology

Freedom Meditech roped in $7 million in a Series B financing round in support of 2 diagnostic products for diabetes management, 1 already on the shelves and 1 still on the bench.

The fundraising was joined by new and returning investors, including funders who participated in a $2.5 million round in 2009. Since Freedom Meditech's founding in 2006, private investors have kicked in more than $10 million to support the company's flagship biomicroscope technology, according to a press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.